Overcoming Disincentives to Process Understanding in the Pharmaceutical CMC Environment - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Overcoming Disincentives to Process Understanding in the Pharmaceutical CMC Environment
Larger and strategic sampling and testing plans can improve process understanding and characterization.

Pharmaceutical Technology

Stability testing. Consider a solution formulation for which the specification requires that the pH be 6.5–7.5. Rather than being based upon clinical fitness for use, these limits were established on the basis of some development data after computing process average 3σ. This means, assuming data follow a normal distribution, that about 3 out of 1000 results are expected to be outside the specification limits because of pure chance. Now assume that the true batch pH is 7.0 and nearly all observed variability is a result of measurement error. Ten units are tested for a batch at each of seven stability time points. Even if the pH is stable during storage, the risk that at least one unit fails to comply with the specification at some time point is at most 1 – (1 – 0.003)70 = 0.19. Clearly, a 19% risk of observing a false out-of-specification (OOS) result for an acceptable batch on stability is intolerable. This failure to conform to specifications also can lead to product recalls of acceptable material. When false OOS signals are obtained as a result of multiplicity, many resources are wasted in the subsequent investigation looking for a root cause that does not exist.

The overall risk of randomly failing somewhere in the stability program increases as more storage conditions and additional annual batches are studied. If multiplicity effects are not taken into account to manage this risk, then manufacturers could be led to a risk-managing approach of reducing the number of batches, conditions, time points, and tested properties as much as possible. Clearly this is at odds with one of the primary objectives of stability testing: to increase the knowledge of the product.

Shelf-life estimation. The recommended approach to shelf life estimation includes a statistical test of batch slope homogeneity (i.e., determining whether there is evidence of a difference in the rate of change over time across batches) (5). It is well known that increasing either the number of batches, the amount of data per batch, or the precision of the measurement process will increase the probability of rejecting the hypothesis of batch slope homogeneity (6). When estimating product shelf life from a group of nonhomogeneous batch slopes, a worst-case strategy is prescribed such that the shelf life for future batches is based on the batch in the group with the shortest shelf life (5). Even when batch slopes are similar, as the amount or precision of data included in a stability program increases, the conditions prescribed to allow pooling of batches are usually less likely to be fulfilled. Therefore, a shorter shelf life is typically obtained. Thus, even though a larger number of batches could lead to a better understanding of product stability, there is a built-in disincentive for a developer to include more than the minimum number of batches (three) for shelf-life estimation.

Process analytical technology. One of the potential applications of PAT is comprehensive real-time evaluation of tablet content uniformity (nondestructive testing of hundreds or thousands of tablets). A challenge in such applications is to properly define the acceptance criteria appropriate for such a large sample. Traditionally, a sample of 10–30 tablets is assessed against criteria specified in the pharmacopeia for uniformity of dosage units (7). These pharmacopeial criteria are not directly applicable to large sample sizes, because they do not take into account the multiplicity risks associated with large samples. An acceptable batch, which passes the pharmacopeia test a high percentage of the time, may fail to have all PAT samples meet the pharmacopeia acceptance criteria. This failure may be attributed to the fact that the range of observed individual values increases with sample size or because the uncertainty in a computed result is based on a sample of different size than that for which the acceptance limit was developed. This issue has been highlighted as a deterrent for extended applications of PAT in this area (8).

Validation and investigations. Frequently in product development and other experimental investigations, including validation and optimization, a scientist may be interested in detecting smaller differences than would be of interest in routine release and stability testing, where the focus is to verify satisfactory product properties. A statistically established approach would be to collect larger amounts of data, possibly following an alternative sampling plan, than the standard release stability test for increased understanding. Because of multiplicity, however, the risk of obtaining individual results outside limits established for a smaller sample size will then increase as a result of common analytical and sampling variation. Because observing such aberrant values will result in "failed" validation, "verified" OOS, or a reduced design space, the consequence is that the size of the testing program is primarily driven by a risk-to-fail assessment rather than the need to obtain more reliable conclusions.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here